FDMDF (4DMedical) YoY EBITDA Growth: -712.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FDMDF 4DMedical Ltd FDMDF
46 GF Score
Price $2.53
GF Value $0.88
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is 4DMedical YoY EBITDA Growth?

4DMedical FDMDF -9.64% 46 YoY EBITDA Growth is -712.00% as of Dec. 2025. GuruFocus rates FDMDF with a GF Score™ of 46/100 and a GF Value™ of $0.88 (Significantly Overvalued). The stock has 2 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. 4DMedical's YoY EBITDA Growth for the quarter that ended in Dec. 2025 was -712.00%.

4DMedical's EBITDA per Share for the six months ended in Dec. 2025 was $-0.20.

4DMedical YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for 4DMedical's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4DMedical YoY EBITDA Growth Chart

4DMedical Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
YoY EBITDA Growth
Get a 7-Day Free Trial -6.35 -77.61 46.22 -1.56 -15.38

4DMedical Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.47 -40.00 0.00 71.43 -712.00
FDMDF
46GF Score
4DMedical Ltd FDMDF
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

4DMedical YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

4DMedical's YoY EBITDA Growth for the fiscal year that ended in Jun. 2025 is calculated as:

YoY EBITDA Growth (A: Jun. 2025 )
=(EBITDA per Share (A: Jun. 2025 )-EBITDA per Share (A: Jun. 2024 ))/ | EBITDA per Share (A: Jun. 2024 ) |
=(-0.075--0.065)/ | -0.065 |
=-15.38 %

4DMedical's YoY EBITDA Growth for the quarter that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (Q: Dec. 2025 )
=(EBITDA per Share (Q: Dec. 2025 )-EBITDA per Share (Q: Dec. 2024 )) / | EBITDA per Share (Q: Dec. 2024 )) |
=(-0.203--0.025)/ | -0.025 |
=-712.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -712.00% mean?
4DMedical (FDMDF) has a YoY EBITDA Growth of -712.00% as of Dec. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for 4DMedical and its competitors.
Is 4DMedical's YoY EBITDA Growth too high?
4DMedical's current YoY EBITDA Growth is -712.00%. Overall, 4DMedical has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 4DMedical's YoY EBITDA Growth compare to ABT and SYK?
4DMedical's YoY EBITDA Growth of -712.00% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Devices & Instruments company?
A good YoY EBITDA Growth depends on the Medical Devices & Instruments industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for 4DMedical and its competitors. 4DMedical's current YoY EBITDA Growth is -712.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4DMedical stock overvalued right now?
Based on GuruFocus' analysis, 4DMedical (FDMDF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.88, compared to a current price of $2.53 — trading 187.5% above its estimated fair value. The current YoY EBITDA Growth is -712.00%. 4DMedical's overall GF Score™ is 46/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For 4DMedical (FDMDF), the current YoY EBITDA Growth is -712.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 4DMedical (FDMDF) Overvalued in 2026?

Based on GuruFocus' analysis, 4DMedical stock appears to be overvalued. The current stock price of $2.53 is trading 187.5% above its estimated GF Value™ of $0.88. GuruFocus considers 4DMedical to be Significantly Overvalued.

Key valuation signals for FDMDF:

  • YoY EBITDA Growth: -712.00%
  • GF Value™: $0.88 vs. price of $2.53 (187.5% above fair value)
  • GF Score™: 46/100 with 2 warning signs

No single metric tells the full story. See the FDMDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

4DMedical Business Description

Other Exchanges MQ7:Germany4DX:Australia
Address 700 Swanston Street, Level 7, Melbourne Connect, Carlton, VIC, AUS, 3053
4DMedical Ltd is a company focused on medical research technology and the development of a non-invasive respiratory imaging solution using four-dimensional imaging. The four-dimensional lung imaging technology utilizes mathematical models and algorithms to convert X-ray scans into quantitative data, aiding physicians in managing patients with respiratory and lung diseases.
46GF Score

Get the complete analysis for FDMDF

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.53
Price
$0.88
GF Value